A Phase 1 interventional study of LY3009104 and Placebo in Healthy Volunteer, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-13.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple doses in Japanese healthy subjects.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2mg administered once on day 1 (single dose)
Drug: LY3009104
5mg administered once on day 1 (single dose)
Drug: LY3009104
10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
Drug: LY3009104
14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
Drug: LY3009104
administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
Drug: Placebo
Administered orally
Also known as: baricitinib
Administered orally
Number of Participants With Clinically Significant Effects
Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.
Time frame: Days 1-10 for Cohorts 1 & 2, Days 1-7 for single dose of Cohorts 3 & 4, Days 8-31 for multiple doses
Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104
Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.
Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104
AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.
Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Pharmacokinetics: Half-Life(t1/2) of LY3009104
Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.
Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Pharmacokinetics: Apparent Volume of Distribution of LY3009104
Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.
Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose
Pharmacokinetics: Apparent Total Body Clearance of LY3009104
Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.
Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose
Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)
Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.
Time frame: Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose
Pharmacokinetics: Renal Excretion of LY3009104
Percentage of LY3009104 excreted in urine from zero to 24 hours.
Time frame: Day 1: continuous for 24 hours
| Milestone | 2 mg LY3009104 (Baricitinib) | 5 mg LY3009104 | 10 mg LY3009104 | 14 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 7 | 9 |
| Received multiple doses of study drug | 0 | 0 | 6 | 6 | 5 |
| Completed | 6 | 6 | 5 | 6 | 8 |
| Not completed | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 0 | 1 |
Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.
| Participants | 2 mg LY3009104 Single Dose | 5 mg LY3009104 Single Dose | 10 mg LY3009104 Single Dose | 14 mg LY3009104 Single Dose | Placebo Single Dose | 10 mg LY3009104 Multiple Dose | 14 mg LY3009104 Multiple Dose | Placebo Multiple Dose |
|---|---|---|---|---|---|---|---|---|
| Serious Adverse Events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nonserious Adverse Events | 1 | 1 | 2 | 7 | 6 | 5 | 4 | 2 |
Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.
| nanomoles/Liter (nmol/L) | 2 mg LY3009104 Day 1 | 5 mg LY3009104 Day 1 | 10 mg LY3009104 Day 1 | 14 mg LY3009104 Day 1 | 10 mg LY3009104 Day 17 | 14 mg LY3009104 Day 17 |
|---|---|---|---|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104 | 76.1 ± 29 | 220 ± 35 | 327 ± 43 | 410 ± 19 | 319 ± 30 | 439 ± 9 |
AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.
| nanomoles*hour/Liter (nmol*h/L) | 2 mg LY3009104 Day 1 | 5 mg LY3009104 Day 1 | 10 mg LY3009104 Day 1 | 14 mg LY3009104 Day 1 | 10 mg LY3009104 Day 17 | 14 mg LY3009104 Day 17 |
|---|---|---|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104 | 403 ± 10 | 1240 ± 23 | 1730 ± 21 | 2790 ± 14 | 1970 ± 18 | 3060 ± 17 |
Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.
| hour (h) | 2 mg LY3009104 Day 1 | 5 mg LY3009104 Day 1 | 10 mg LY3009104 Day 1 | 14 mg LY3009104 Day 1 | 10 mg LY3009104 Day 17 | 14 mg LY3009104 Day 17 |
|---|---|---|---|---|---|---|
| Pharmacokinetics: Half-Life(t1/2) of LY3009104 | 5.19 (3.88 to 6.31) | 6.82 (5.70 to 7.79) | 6.43 (4.37 to 9.90) | 8.48 (6.95 to 10.8) | 8.57 (7.43 to 9.30) | 9.41 (7.24 to 13.1) |
Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.
| Liter (L) | 2 mg LY3009104 Day 1 | 5 mg LY3009104 Day 1 | 10 mg LY3009104 Day 1 | 14 mg LY3009104 Day 1 | 10 mg LY3009104 Day 17 | 14 mg LY3009104 Day 17 |
|---|---|---|---|---|---|---|
| Pharmacokinetics: Apparent Volume of Distribution of LY3009104 | 96.3 ± 18 | 99.4 ± 29 | 138 ± 41 | 150 ± 19 | 169 ± 24 | 167 ± 23 |
Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.
| Liter/hour (L/h) | 2 mg LY3009104 Day 1 | 5 mg LY3009104 Day 1 | 10 mg LY3009104 Day 1 | 14 mg LY3009104 Day 1 | 10 mg LY3009104 Day 17 | 14 mg LY3009104 Day 17 |
|---|---|---|---|---|---|---|
| Pharmacokinetics: Apparent Total Body Clearance of LY3009104 | 12.9 ± 11 | 10.1 ± 22 | 14.8 ± 20 | 12.2 ± 17 | 13.7 ± 18 | 12.3 ± 17 |
Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.
| hour (h) | 2 mg LY3009104 Day 1 | 5 mg LY3009104 Day 1 | 10 mg LY3009104 Day 1 | 14 mg LY3009104 Day 1 | 10 mg LY3009104 Day 17 | 14 mg LY3009104 Day 17 |
|---|---|---|---|---|---|---|
| Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax) | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 1.00) | 1.25 (0.50 to 2.00) | 1.00 (0.50 to 2.10) | 1.00 (0.50 to 2.00) | 1.00 (1.00 to 1.00) |
Percentage of LY3009104 excreted in urine from zero to 24 hours.
| percentage of drug | 10 mg LY3009104 Day 1 | 14 mg LY3009104 Day 1 |
|---|---|---|
| Pharmacokinetics: Renal Excretion of LY3009104 | 75.8 ± 7 | 63.6 ± 13 |
Collected over From starting of the dose to follow-up. Adverse events (AE) for single dose were observed from Day 1 to Day 10±2 days (Cohorts 1&2) or Day 7 (Cohorts 3&4). AE for multiple doses were observed from Day 8 to Day 31±3 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 mg LY3009104 - Single Dose | — | 0/6 (0%) | 1/6 (16.7%) |
| 5 mg LY3009104 - Single Dose | — | 0/6 (0%) | 1/6 (16.7%) |
| 10 mg LY3009104 - Single Dose | — | 0/6 (0%) | 2/6 (33.3%) |
| 14 mg LY3009104 - Single Dose | — | 0/7 (0%) | 7/7 (100%) |
| Placebo - Single Dose | — | 0/9 (0%) | 6/9 (66.7%) |
| 10 mg LY3009104 - Multiple Dose | — | 0/6 (0%) | 5/6 (83.3%) |
| 14 mg LY3009104 - Multiple Dose | — | 0/6 (0%) | 4/6 (66.7%) |
| Placebo - Multiple Dose | — | 0/5 (0%) | 2/5 (40%) |
| Event | 2 mg LY3009104 - Single Dose | 5 mg LY3009104 - Single Dose | 10 mg LY3009104 - Single Dose | 14 mg LY3009104 - Single Dose | Placebo - Single Dose | 10 mg LY3009104 - Multiple Dose | 14 mg LY3009104 - Multiple Dose | Placebo - Multiple Dose |
|---|---|---|---|---|---|---|---|---|
| Neutrophil Count DecreasedInvestigations | 0/6 | 0/6 | 0/6 | 5/7 | 0/9 | 1/6 | 3/6 | 0/5 |
| Vessel Puncture Site HaematomaGeneral disorders | 1/6 | 1/6 | 0/6 | 3/7 | 1/9 | 1/6 | 0/6 | 0/5 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/9 | 2/6 | 0/6 | 0/5 |
| HeadacheNervous system disorders | 1/6 | 0/6 | 1/6 | 0/7 | 3/9 | 2/6 | 1/6 | 0/5 |
| ExcoriationInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/7 | 2/9 | 0/6 | 0/6 | 0/5 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/7 | 0/9 | 1/6 | 1/6 | 1/5 |
| Skin LacerationInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/7 | 0/9 | 0/6 | 0/6 | 1/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/9 | 0/6 | 1/6 | 1/5 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/9 | 1/6 | 0/6 | 1/5 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 1/6 | 1/7 | 0/9 | 0/6 | 0/6 | 1/5 |
| Age, Continuous(years) | 2 mg LY3009104 | 5 mg LY3009104 | 10 mg LY3009104 | 14 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 46.3 ± 10.8 | 48.0 ± 15.0 | 46.7 ± 9.0 | 51.1 ± 6.3 | 45.1 ± 10.7 | 47.4 ± 10.2 |
| Sex: Female, Male(Participants) | 2 mg LY3009104 | 5 mg LY3009104 | 10 mg LY3009104 | 14 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 2 | 3 | 2 | 2 | 12 |
| Male | 3 | 4 | 3 | 5 | 7 | 22 |
| Race/Ethnicity, Customized(Participants) | 2 mg LY3009104 | 5 mg LY3009104 | 10 mg LY3009104 | 14 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Asian | 6 | 6 | 6 | 7 | 9 | 34 |
| Region of Enrollment(Participants) | 2 mg LY3009104 | 5 mg LY3009104 | 10 mg LY3009104 | 14 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 7 | 9 | 34 |
The record gives a start of Nov 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 7 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib